Fuller & Thaler Asset Management’s Progenics Pharmaceuticals Inc PGNX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q3 | – | Sell |
-312,800
| Closed | -$2.52M | – | 778 |
|
|
2018
Q2 | $2.52M | Sell |
312,800
-100
| -0% | -$804 | 0.03% | 282 |
|
|
2018
Q1 | $2.33M | Sell |
312,900
-24,900
| -7% | -$186K | 0.03% | 262 |
|
|
2017
Q4 | $2.01M | Sell |
337,800
-106,400
| -24% | -$633K | 0.02% | 264 |
|
|
2017
Q3 | $3.27M | Sell |
444,200
-2,100
| -0.5% | -$15.5K | 0.04% | 202 |
|
|
2017
Q2 | $3.03M | Sell |
446,300
-1,700
| -0.4% | -$11.5K | 0.04% | 189 |
|
|
2017
Q1 | $4.23M | Hold |
448,000
| – | – | 0.06% | 162 |
|
|
2016
Q4 | $3.87M | Hold |
448,000
| – | – | 0.06% | 161 |
|
|
2016
Q3 | $2.84M | Sell |
448,000
-12,900
| -3% | -$81.7K | 0.05% | 173 |
|
|
2016
Q2 | $1.95M | Buy |
460,900
+100
| +0% | +$422 | 0.03% | 192 |
|
|
2016
Q1 | $2.01M | Sell |
460,800
-147,100
| -24% | -$641K | 0.04% | 180 |
|
|
2015
Q4 | $3.73M | Buy |
607,900
+29,200
| +5% | +$179K | 0.08% | 159 |
|
|
2015
Q3 | $3.31M | Buy |
578,700
+400
| +0.1% | +$2.29K | 0.09% | 156 |
|
|
2015
Q2 | $4.31M | Buy |
578,300
+12,100
| +2% | +$90.3K | 0.12% | 142 |
|
|
2015
Q1 | $3.39M | Sell |
566,200
-1,800
| -0.3% | -$10.8K | 0.11% | 171 |
|
|
2014
Q4 | $4.29M | Buy |
568,000
+8,500
| +2% | +$64.3K | 0.15% | 148 |
|
|
2014
Q3 | $2.9M | Hold |
559,500
| – | – | 0.12% | 169 |
|
|
2014
Q2 | $2.41M | Buy |
559,500
+53,500
| +11% | +$231K | 0.1% | 186 |
|
|
2014
Q1 | $2.07M | Buy |
+506,000
| New | +$2.07M | 0.1% | 205 |
|